CSIMarket Company Name, Ticker, Customers, else..
 
Aslan Pharmaceuticals Limited  (NASDAQ: ASLN)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 402
 Employees -
 Revenues (TTM) (Millions $) 12
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) 57
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aslan Pharmaceuticals Limited is a biopharmaceutical company that focuses on the development of innovative therapeutics for oncology and immunology. They utilize precision medicine approaches to develop targeted therapies for patients with unmet medical needs. Aslan Pharmaceuticals has a diverse pipeline of drug candidates, including both small molecule and antibody therapies. They collaborate with leading academic institutions and research organizations to advance their drug development programs.


   Company Address: 3 Temasek Avenue Level 18 Centennial Tower Singapore 39190
   Company Phone Number: 6817 9598   Stock Exchange / Ticker: NASDAQ ASLN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

ASLAN Pharmaceuticals Faces Nasdaq Delisting After Failing to Meet Listing Requirements, Future Remains Uncertain

Published Mon, Jul 15 2024 11:30 AM UTC


On July 9, 2024, ASLAN Pharmaceuticals received notification from the staff of the Listing Qualifications Department at Nasdaq regarding its non-compliance with the $1.00 bid price and $2.5 million stockholders equity requirements, as outlined in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).
After careful consideration by the company s board of directors, ASLAN Ph...
Stocks on the Move

The Rising Potential and Market Challenges for ASLAN Pharmaceuticals Ltd ADR (ASLN) Stock

Published Tue, Jul 9 2024 3:10 PM UTC

ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) has been gaining significant attention in the biotechnology and medical research industry. Recent developments, including a positive rating upgrade and fluctuations in stock performance, have attracted the interest of investors and analysts alike. In this article, we will analyze the key events surrounding ASLAN Pharmaceuticals an...
Shares

ASLAN Pharmaceuticals Adjusts ADS Ratio, Impacting Shareholders and Stock Price

Published Fri, Jun 14 2024 8:54 PM UTC


ASLAN Pharmaceuticals, a leading biopharmaceutical company, recently announced plans to change the ratio of its American Depositary Shares (ADSs) to ordinary shares. This change, from one ADS representing twenty-five ordinary shares to one ADS representing two hundred ordinary shares, has significant implications for shareholders and the overall stock price.
This de...
Partnership

ASLAN Pharmaceuticals and Zenyaku Expand Collaboration to Investigate Unique Biology of Eblasakimab in Atopic Dermatitis Treatment

Published Thu, May 2 2024 1:00 PM UTC

ASLAN Pharmaceuticals Expands Collaboration with Zenyaku to Investigate Eblasakimab s Unique Biology in Comparison to Other BiologicsMay 2, 2024 ASLAN Pharmaceuticals (Nasdaq: ASLN) has recently announced an extension of its research collaboration agreement with Zenyaku Kogyo Co., Ltd. (Zenyaku), aiming to delve deeper into the distinct mechanism of action exhibited by the...
Product Service News

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Published Mon, Apr 22 2024 12:45 PM UTC

Groundbreaking Eblasakimab Shows Remarkable Efficacy in Dupilumab-Experienced Atopic Dermatitis PatientsASLAN Pharmaceuticals, a pioneering biopharmaceutical company, recently revealed promising interim results from a phase 2 study investigating the use of eblasakimab in patients with atopic dermatitis who have been previously treated with dupilumab.Atopic dermatitis, a chro...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.86
Working Capital Ratio 0.97
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.11 $
Revenues (TTM) 0.03 $
Cash Flow (TTM) 0.14 $
Cash 0.05 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.37

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -364.46 %
Net Margin (MRQ) -368.5 %
Net Cash Flow Margin (MRQ) 474.18 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.